x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

2:29

Pharmaceutical Executive Daily: Bayer Shares Drop...

Pharmaceutical Executive ·

2026/03/24

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, Quotient Therapeutics enters a multi-year research collaboration with Merck to discover novel drug targets in inflammatory bowel disease, and Gilead Sciences agrees to acquire privately held Ouro Medicines in a deal valued at up to $2.18 billion.

en-us

2:41

Pharmaceutical Executive Daily: Pfizer Warns...

Pharmaceutical Executive ·

2026/03/23

In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase up to one million shares at a potentially below-market price, the FDA grants expanded approval to Rhythm Pharmaceuticals' Imcivree as the first approved treatment for acquired hypothalamic obesity, and a new commentary makes the case that AI-powered roleplay data is an untapped source of commercial intelligence for pharma field teams.

en-us

2:56

Pharmaceutical Executive Daily: FDA Approves Wegovy HD

Pharmaceutical Executive ·

2026/03/20

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire Azstarys from Corium Therapeutics, the FDA grants accelerated approval to Wegovy HD, a higher-dose version of Novo Nordisk's semaglutide injection, supported by Phase III data showing roughly 21% mean weight loss, and an analysis on agentic AI and what it means for commercial operations in life

en-us

10:17

The Ron Lanton Report: When Policy Becomes a Capital...

Pharmaceutical Executive ·

2026/03/20

The episode explores how regulatory signals across drug approvals, trade policy, AI governance, and drug pricing shape business strategy and investor decisions before formal rules are ever finalized.

en-us

2:33

Pharmaceutical Executive Daily: Analysis on TrumpRx...

Pharmaceutical Executive ·

2026/03/19

In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two biotech companies focused on next-generation T-cell engager therapies close significant funding rounds, and Pharmaceutical Executive sits down with Jeanne Marrazzo of the Infectious Diseases Society of America on the worsening U.S. measles outbreak and what it means for the future of vaccine confidence.

en-us

2:36

Pharmaceutical Executive Daily: Federal Judge Halts...

Pharmaceutical Executive ·

2026/03/18

In today's Pharmaceutical Executive Daily, a federal judge blocks RFK Jr.'s reconstituted vaccine advisory committee and halts its policy changes, a new analysis breaks down what recent Gartner predictions on AI mean for healthcare marketers, and the FDA approves Icotyde as the first oral targeted therapy for moderate-to-severe plaque psoriasis.

en-us

2:08

Pharmaceutical Executive Daily: Conflict in Middle...

Pharmaceutical Executive ·

2026/03/16

In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl Therapeutics enters a licensing agreement with PRG-ST to advance a progerin-targeting therapy for progeria, and a new analysis examines the innovations, integration challenges, and early hurdles shaping the emerging biotech landscape.

en-us

2:31

Pharmaceutical Executive Daily: FDA Expands Approval...

Pharmaceutical Executive ·

2026/03/13

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the approved age indication for GSK's RSV vaccine Arexvy to adults aged 18 to 49 at increased risk, and a new commentary argues that agentic AI is positioned to fundamentally reshape commercial operations in life sciences.

en-us

2:35

Pharmaceutical Executive Daily: Senate Democrats...

Pharmaceutical Executive ·

2026/03/12

en-us

8:16

Moving CAR-T Beyond Oncology

Pharmaceutical Executive ·

2026/03/11

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

en-us

2:27

Pharmaceutical Executive Daily: FDA's New Guidance...

Pharmaceutical Executive ·

2026/03/11

In today's Pharmaceutical Executive Daily, the FDA issues new draft guidance aimed at reducing the cost and complexity of biosimilar development, Novo Nordisk responds to an FDA warning letter stemming from a 2025 inspection of its U.S. headquarters, and Pharmaceutical Executive's latest analysis examines the state of the biopharma industry as it navigates a period of cautious momentum.

en-us

2:24

Pharmaceutical Executive Daily: FDA Expands Approval...

Pharmaceutical Executive ·

2026/03/10

In today's Pharmaceutical Executive Daily, the FDA approves leucovorin as the first-ever treatment for an ultra-rare genetic condition called cerebral folate transport deficiency, Enhertu receives FDA Priority Review for HER2-positive early breast cancer in the post-neoadjuvant setting, and a new commentary argues that AI has fundamentally changed how healthcare communicators must think about content strategy.

en-us

1:50

Pharmaceutical Executive Daily: Vinay Prasad Set to...

Pharmaceutical Executive ·

2026/03/09

In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under a year, major deal activity including a GSK and Alfasigma licensing agreement along with Servier’s $2 billion acquisition of Day One Pharmaceuticals, and Ipsen withdraws Tazverik from the market following emerging clinical trial data.

en-us

2:00

Pharmaceutical Executive Daily: Cognito Therapeutics...

Pharmaceutical Executive ·

2026/03/05

In today’s Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intelligence and large language models reshape pharmacovigilance and drug safety monitoring, and Eli Lilly launches a new Employer Connect platform to expand obesity treatment coverage options.

en-us

1:57

Pharmaceutical Executive Daily: Pharma Industry's AI...

Pharmaceutical Executive ·

2026/03/04

In today’s Pharmaceutical Executive Daily, Antengene and UCB enter a billion-dollar global licensing agreement for a bispecific T-cell engager, Teva signs a $400 million strategic growth capital agreement with Blackstone Life Sciences, and industry leaders explore the technological renaissance driven by AI integration.

en-us

16:53

The Ongoing Impact of MFN Pricing

Pharmaceutical Executive ·

2026/03/04

Alice Valdur Curan discusses how the industry continues to strategize around this complicated order.

en-us

1:50

Pharmaceutical Executive Daily: Novo Nordisk Commits...

Pharmaceutical Executive ·

2026/03/03

In today’s Pharmaceutical Executive Daily, industry leaders examine how to measure AI’s return on investment across the life sciences value chain, Novo Nordisk commits $506 million to expand its Ireland manufacturing facility, and Bavarian Nordic CEO Paul Chaplin announces plans to step down.

en-us

1:51

Pharmaceutical Executive Daily: FDA Approves Palynziq...

Pharmaceutical Executive ·

2026/03/02

In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older, Sogroya becomes the first and only weekly long-acting growth hormone approved for pediatric use, and experts examine how real-world data strengthens natural history disease research.

en-us

1:43

Pharmaceutical Executive Daily: FDA Approves Hernexeos

Pharmaceutical Executive ·

2026/02/27

In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry leaders explore the expansion of direct-to-consumer HIV prevention strategies, and Dupixent gains FDA approval for allergic fungal rhinosinusitis.

en-us

1:41

Pharmaceutical Executive Daily: Alkermes' CEO...

Pharmaceutical Executive ·

2026/02/26

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.

en-us

316 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter